Alnylam Pharmaceuticals
ALNY
#1140
Rank
C$27.62 B
Marketcap
C$206.22
Share price
-2.71%
Change (1 day)
-66.49%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2026 (TTM): C$28.10

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is C$28.41. In 2025 the company made an earnings per share (EPS) of C$2.52.

EPS history for Alnylam Pharmaceuticals from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)C$28.101013.47%
2025C$2.52
2023C-$5.06-62%
2022C-$13.3229.03%
2021C-$10.32-3.36%
2020C-$10.68-8.48%
2019C-$11.677.67%
2018C-$10.8439.74%
2017C-$7.7612.94%
2016C-$6.8738.84%
2015C-$4.95-32.88%
2014C-$7.37259.44%
2013C-$2.05-31.25%
2012C-$2.98

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
C$7.53-73.50%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
C$2.84-90.00%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
C$67.36 137.15%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
C-$3.77-113.28%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
C-$1.05-103.69%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
C-$0.27-100.96%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
C$0.65-97.73%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
C-$4.77-116.81%๐Ÿ‡บ๐Ÿ‡ธ USA